-
Up to today
- license agreement signed with Myung In Pharm for evenamide in South Korea
-
license agreement signed with EA Pharma for evenamide
- exceptional 1 year results of study 014/15 in TRS
- positive top-line results from study 008A in schizophrenia
-
Evenamide
- striking six-month results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
-
Evenamide
- encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS)
-
Evenamide Phase II/III
- initiation of Study 008A, the 1st potentially pivotal study with evenamide in patients with schizophrenia
- initiation of pilot Study 014: evenamide as add-on treatment in patient wih moderated to severeTRS
- initial results from two short-…
-
Working to progress the development of evenamide
- Safinamide has now been successfully launched in 18 countries
- Shares listed also on the primary market of the Düsseldorf Stock Exchange and on XETRA
-
Xadago® (safinamide) approved by US FDA
received EUR 11.3m milestone payments from Zambon
-
Xadago® (safinamide) approved in EU
-
progress in development and new alliance
- Completion of the Phase III for Safinamide
- License agreements with Meji Seika Pharma and Zambon for Safinamide
- US FDA IND approval for NW-3509 (2011)
-
IPO on the SWX Swiss Exchange
€74.3m raised - one of the top 3 global biotech IPOs of this year
